Skip to main content

Table 2 Known genetic alterations characterizing the NSCLC lines used in the paper. Information about genetic defects were retrieved from the database of the Wellcome Trust Sanger Institute Catalogue Of Somatic Mutations In Cancer COSMIC, https://cancer.sanger.ac.uk/cell_lines)

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Cell line Hystotype Mutational status
TP53 EGFR KRAS Other mutations/molecular alterations
Calu-6 anaplastic carcinoma mut wt Q61K JAK1, BRCA1, p16INK4A methylation
SK-Lu-1 adenocarcinoma mut wt G12D KIT, CSF3R, FLT4
NCI-H1975 adenocarcinoma mut L858R + T790 M wt PDGFRA, PIK3CA
NCI-H2228 adenocarcinoma mut wt wt ALK translocation, PDGFRA, RB